Through HSP90 binding and the activation of Akt, survivin is potentiated to inhibit apoptosis and secure CSC survival as a preclinical observation seen in melanoma, breast cancer, cervical cancer, colon cancer, and embryonic kidney cells. The gene discussed is HSP90AB1; the disease is melanoma.